Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Monday agreed to acquire Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) for $85 per share in cash, a total equity value of approximately $10 billion ($8.8 billion net of cash).
Vertex expects to finance the acquisition using a combination of cash on hand and debt, supported by $4.5 billion of fully committed bridge financing.
Vertex’s cash, cash equivalents, and total marketable securities as of March 31, 2026, were $13.0 billion.
The transaction was approved by both the Vertex and Crinetics Boards of Directors and is anticipated to close in the third quarter of 2026.
Palsonify And Atumelnant Expand Vertex’s Rare Disease Portfolio
“Crinetics is an excellent strategic fit for Vertex,” said Reshma Kewalramani, CEO and President of Vertex.
Crinetics’ marketed medicine, Palsonify (paltusotine), received FDA approval in September 2025.
The European Medicines Agency recently approved Palsonify.
It is the first and only once-daily oral therapy for adults with acromegaly, a rare and debilitating condition caused by a pituitary tumor that secretes excess growth hormone, which affects an estimated 20,000 diagnosed people in the U.S.
Crinetics’ most advanced pipeline candidate, atumelnant, is a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist currently in Phase 3 development for congenital adrenal hyperplasia (CAH).
Classic CAH, the most severe form of the disease, with 17,000 addressable patients in the U.S., is a rare, chronic genetic condition affecting the adrenal glands.
In Phase 2 studies, patients taking atumelnant were able to achieve near normalization of excess androgen levels on physiologic replacement doses of glucocorticoids.
Vertex Expects Revenue And Profit Growth From Acquisition
The transaction is expected to contribute immediately to Vertex’s revenue growth via the ongoing launch of Palsonify, which has blockbuster potential in acromegaly.
Longer term, atumelnant has the potential to be a multi-billion-dollar opportunity in CAH, with additional upside from its potential in Cushing’s syndrome.
At peak, these assets have the potential to deliver more than $5 billion in combined annual revenue, which will further Vertex’s goal of delivering sustained double-digit revenue growth, in addition to operating margins.
The transaction is expected to become accretive to adjusted operating income in 2029.
Analyst Sees Upside
William Blair on Monday wrote, “…it is the first time we have heard of a multi-billion dollar sales potential for a CAH product.”
Analyst Myles Minter further added that the deal is on the higher side on a stock price premium basis, but views this as reasonable if the peak sales number can be achieved.
William Blair also wrote, “Based on management commentary, we believe significantly more of the >$5 billion peak sales potential is weighted toward the atumelnant opportunity, which carries more risk given the late-clinical-stage nature of the ACTH receptor antagonist.”
Price Action: Crinetics Pharmaceuticals shares were up 98.88% at $83.59, and Vertex Pharmaceuticals shares were down 0.30% at $528.00 during premarket trading on Tuesday, according to Benzinga Pro data.
Photo: courtesy of Vertex
